title: Immune checkpoint blockade in ovarian cancer.
abstract: Increased numbers of tumour infiltrating T‑cells have long been associated with a better prognosis in ovarian cancer, which has led to the general assumption of a relevant impact of T‑cellular anti-tumour immunity in this disease. As a consequence of this knowledge, a multitude of immunologic therapies has emerged over the past years. Although some reports could evidence a successful induction of anti-tumour T‑cells, in general, these attempts did not translate into clinically significant activity. As has already been shown in other tumour entities, immune checkpoint blockade - mainly antibodies directed against PD-1 and PD-L1 - could possibly become a real "game changer" in ovarian cancer in the future.
authors.affiliation: 3rd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute (SCRI), Muellner Hauptstraße 48, 5020 Salzburg, Austria.
authors.forename: Lukas
authors.initials: L
authors.lastname: Weiss
authors.affiliation: 3rd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute (SCRI), Muellner Hauptstraße 48, 5020 Salzburg, Austria.
authors.forename: Florian
authors.initials: F
authors.lastname: Huemer
authors.affiliation: 3rd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute (SCRI), Muellner Hauptstraße 48, 5020 Salzburg, Austria.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Mlineritsch
authors.affiliation: 3rd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute (SCRI), Muellner Hauptstraße 48, 5020 Salzburg, Austria.
authors.forename: Richard
authors.initials: R
authors.lastname: Greil
keywords: Immune checkpoint; Immunotherapy; Ovarian cancer; PD-1; PD-L1